indinavir-sulfate and Amyotrophic-Lateral-Sclerosis

There is some evidence of retroviral infection in ALS. A randomized, double-blind, placebo-controlled trial of indinavir in ALS was performed to assess safety and efficacy trends. Nephrolithiasis and gastrointestinal side effects were frequent with indinavir treatment. Group differences in the rate of decline were not significant between the groups for the ALS Functional Rating Scale (p = 0.36) or for the secondary variables. The toxicity and negative efficacy trends discourage further indinavir trials in ALS.

Topics: Amyotrophic Lateral Sclerosis; Central Nervous System; Double-Blind Method; Female; HIV Protease Inhibitors; Humans; Indinavir; Kidney Calculi; Male; Middle Aged; Neuroprotective Agents; Pilot Projects; Placebos; Riluzole; Treatment Failure

Reverse transcriptase has been detected in the serum of HIV-negative patients with amyotrophic lateral sclerosis (ALS). An ALS-like disorder in HIV-positive patients can remit with antiretroviral therapy. Using the product enhanced assay technique, we measured reverse transcriptase activity in the serum and CSF of 23 HIV-negative patients with ALS and 21 neurologic disease controls. Results for CSF were not significant, whereas reverse transcriptase was detected in 56% of ALS sera vs 19% of controls.

Topics: Adult; Aged; Amyotrophic Lateral Sclerosis; Blood Protein Electrophoresis; Female; HIV; HIV Protease Inhibitors; HIV Seronegativity; Humans; Indinavir; Male; Middle Aged; Polymerase Chain Reaction; Randomized Controlled Trials as Topic; RNA-Directed DNA Polymerase